JW Therapeutics Acquires Syracuse Biopharma and License to Eureka Therapeutics’ Solid Tumor…
JW Therapeutics announced the acquisition of Syracuse Biopharma (Hong Kong) Limited, which includes the license for Eureka Therapeutics’ ARTEMIS antibody TCR and solid tumor technology…
Read More...
Read More...
